Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Robbins Farley

Robbins Farley grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,362 shares of the medical research company’s stock after buying an additional 258 shares during the quarter. Robbins Farley’s holdings in Edwards Lifesciences were worth $2,100,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in EW. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the period. State Street Corp boosted its position in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after purchasing an additional 284,918 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after purchasing an additional 806,705 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $555,939,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Barclays raised their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Piper Sandler decreased their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $79.19.

Edwards Lifesciences Trading Down 1.4 %

Edwards Lifesciences stock opened at $71.46 on Tuesday. The business’s 50-day simple moving average is $72.49 and its 200-day simple moving average is $69.73. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a market capitalization of $42.15 billion, a PE ratio of 10.31, a PEG ratio of 3.72 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,000 shares of company stock valued at $547,430. Insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.